Location of cis-acting signals important for RNA encapsidation in the leader sequence of human immunodeficiency virus type 2.
about
Destiny of Unspliced Retroviral RNA: Ribosome and/or Virion?Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2Identification of unique reciprocal and non reciprocal cross packaging relationships between HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral vector system with highly favourable features for in vivo testing and clinical usageTsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag.Translation is not required To generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells.Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus.Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation.Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virionsHuman immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidationA structural linkage between the dimerization and encapsidation signals in HIV-2 leader RNA.Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions.The simian immunodeficiency virus 5' untranslated leader sequence plays a role in intracellular viral protein accumulation and in RNA packaging.An extended stem-loop 1 is necessary for human immunodeficiency virus type 2 replication and affects genomic RNA encapsidation.HIV-2 RNA dimerization is regulated by intramolecular interactions in vitro.HIV-2 genome dimerization is required for the correct processing of Gag: a second-site reversion in matrix can restore both processes in dimerization-impaired mutant virusesRegulation of primate lentiviral RNA dimerization by structural entrapment.The secondary structure of the 5' end of the FIV genome reveals a long-range interaction between R/U5 and gag sequences, and a large, stable stem-loopRandomization and in vivo selection reveal a GGRG motif essential for packaging human immunodeficiency virus type 2 RNAA 5'UTR-spliced mRNA isoform is specialized for enhanced HIV-2 gag translation.Structural dynamics of retroviral genome and the packagingIn vitro characterization of a base pairing interaction between the primer binding site and the minimal packaging signal of avian leukosis virus genomic RNATranslation initiation of the HIV-1 mRNA.Encapsidation determinants located downstream of the major splice donor in the maedi-visna virus leader regionDifferent effects of the TAR structure on HIV-1 and HIV-2 genomic RNA translation.Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors.Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line.The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: cotranslational RNA encapsidation and limitation of Gag protein confer specificity.Mapping the encapsidation determinants of feline immunodeficiency virus.Dimerisation of HIV-2 genomic RNA is linked to efficient RNA packaging, normal particle maturation and viral infectivity.Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239.A novel approach for producing lentiviruses that are limited to a single cycle of infection.
P2860
Q22242227-F1E3E418-F59B-414E-B34C-3AC07DF43257Q24305530-B2B2D8CD-B2FF-48A0-A023-EDBEE7379C1AQ24810805-96038C74-74F2-48D9-BBEA-A3C61DBFA5A1Q30865002-8B21FAE7-0AEA-4048-99F5-FA9C2A1A4F25Q30968445-ACFD1BE8-17E9-4634-A1B8-F150AD7E92E6Q33604023-6C67B539-2143-4EB9-B038-90D9602C7959Q33785662-00C178BC-5DAE-43FE-B601-38A75F8E6FBDQ33851781-01748308-3E12-4163-B7CE-C59A4A948297Q33854807-28044030-ADC1-4EE0-A4DB-5B29BBA169FAQ34365248-50A82701-61B1-4A84-85F7-F4EDE374DFD3Q34673247-6FB7D9A0-2475-44B1-A88B-FF44D9816643Q34996384-C1B95109-0E58-4F01-B5B4-06FB37A0A15CQ35785204-C1E4542B-69EC-405E-8FED-AE94951CA568Q35902030-755482D5-5228-43AD-A538-671DAE770CDBQ35943592-089A82FD-8903-4909-8207-94D58C6A7169Q36807232-30DFFF0F-7298-409D-A1F2-4BA8045449DAQ36990757-49986314-E3FF-4032-92C4-9F358EFF5506Q37033338-D6A6A100-C8F8-4731-A0C1-2F465381FAECQ37361258-C619B436-5897-4142-BAB6-E2044EFBC9B9Q37974642-CB9E6542-5902-43C0-B8ED-F95224B03F5CQ38347263-F11B7A8C-1B72-4690-9B25-C51000F6535FQ38700670-22AAD03D-F88F-470E-BA87-26164152DF6BQ39321671-167592B1-AA3A-4CE3-9EF6-2A1EF4916B95Q39436460-46AB383D-F8A9-4615-8EE6-4B7636DA5822Q39579490-1BCCF455-9E07-43E4-A37D-8D18EB4231A4Q39582470-F4768237-0AF5-42B8-9E86-64B27BB9C44DQ39611117-98CC898B-F170-49A8-AC47-569866385B9AQ39686316-0C14EACB-D4FF-4CFA-85BF-199F404FFC9AQ40035872-A8251176-0608-421A-9FA1-C455D88D1B89Q40191361-B7F2DF68-C915-409E-924F-44118E7C5AA3Q40212983-7D760683-E6FC-4B48-A5EE-17E2E6C48AA2
P2860
Location of cis-acting signals important for RNA encapsidation in the leader sequence of human immunodeficiency virus type 2.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Location of cis-acting signals ...... immunodeficiency virus type 2.
@ast
Location of cis-acting signals ...... immunodeficiency virus type 2.
@en
type
label
Location of cis-acting signals ...... immunodeficiency virus type 2.
@ast
Location of cis-acting signals ...... immunodeficiency virus type 2.
@en
prefLabel
Location of cis-acting signals ...... immunodeficiency virus type 2.
@ast
Location of cis-acting signals ...... immunodeficiency virus type 2.
@en
P2860
P1433
P1476
Location of cis-acting signals ...... immunodeficiency virus type 2
@en
P2093
P2860
P304
P407
P577
1997-05-01T00:00:00Z